Related Experiment Video

Updated: Mar 22, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.4K

Homologous recombination deficiency and ovarian cancer

Jonathan A Ledermann1, Yvette Drew2, Rebecca S Kristeleit1

  • 1UCL Cancer Institute, London, UK.

European Journal of Cancer (Oxford, England : 1990)
|April 12, 2016
PubMed

Insights

PARP inhibitors offer a new treatment for ovarian cancer by targeting DNA repair deficiencies. These drugs are effective in BRCA-mutated cancers and may benefit others with homologous recombination deficiency.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • PARP inhibitors target DNA repair pathways.
  • BRCA1/BRCA2 proteins are crucial for DNA double-strand break repair via homologous recombination repair (HRR).
  • Homologous Recombination Deficiency (HRD) is a key target for PARP inhibitors in ovarian cancer.

Purpose of the Study:

  • To explore PARP inhibitors as a therapeutic strategy for high-grade ovarian cancers.
  • To highlight the role of BRCA mutations and HRD in ovarian cancer treatment.
  • To discuss the clinical implications and future directions for PARP inhibitor therapy.

Main Methods:

  • Review of the mechanism of action of PARP inhibitors.
  • Analysis of the role of BRCA mutations and HRD in ovarian cancer.
  • Discussion of clinical trial data and regulatory approvals for PARP inhibitors.

Main Results:

  • Olaparib, the first PARP inhibitor, is approved for BRCA-mutated ovarian cancers.
  • PARP inhibitors demonstrate selective efficacy in high-grade ovarian cancers.
  • HRD is the first phenotypically defined predictive marker for PARP inhibitor therapy in ovarian cancer.

Conclusions:

  • PARP inhibitors represent a significant advancement in treating high-grade ovarian cancers, particularly those with BRCA mutations.
  • Testing for BRCA mutations should be integrated into routine clinical practice for ovarian cancer patients.
  • Further validation is needed for the expanded use of PARP inhibitors in HRD-deficient tumors without BRCA mutations.
Keywords:
BRCA1BRCA2DNA repairHRDHomologous recombination deficiencyHomologous recombination repairOlaparibOvarian cancerPARP inhibitors

More Related Videos

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence06:25

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence

Published on: February 10, 2023

2.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Crossing Over01:30

Crossing Over

Crossing over is the exchange of genetic information between homologous chromosomes during prophase I of meiosis I. Genetic recombination gives rise to allelic diversity in the newly formed daughter cells. In humans, crossing over produces genetically distinct haploid egg and sperm cells that undergo fertilization to produce unique offspring. Before cell division starts, the germ cell’s chromosome(s) undergo duplication in the S phase of the cell cycle. As the cells enter prophase I,...
7.1K
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
65.2K
Homologous Recombination02:31

Homologous Recombination

7.3K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
7.3K
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
71.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K